You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

93 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    chlorambucil
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
chlorambucil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2018
Cancer facts
Nov 2018
Guidelines and Advice
Status: Current
ID: pet 2018-1
Version: n/a
Oct 2018
Cancer facts
Dec 2018
Guidelines and Advice
Status: Current
ID: GL 21-2v2
Version: 2
Nov 2018
Guidelines and Advice
Status: Current
ID: N/A
Version: 1
Nov 2018
Guidelines and Advice
Status: Current
ID: PET 19
Version: n/a
Nov 2018
Guidelines and Advice
Status: Current
ID: N/A
Version: 1
Mar 2018
Guidelines and Advice
Status: In-Review
ID: 7-14
Version: 3
Dec 2018
Guidelines and Advice
Status: Current
ID: N/A
Version: Final
May 2018
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab Emtansine - Adjuvant Treatment for Early Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
Kadcyla trastuzumab emtansine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2023
Guidelines and Advice
Status: In-Review
ID: ES 15-16
Oct 2018

Pages